Wiener klinische Wochenschrift

, Volume 120, Issue 11–12, pp 321–324 | Cite as

Parathyroid hormone analogues in the therapy of osteoporosis

Perspective
  • 65 Downloads

Keywords

Teriparatide rhPTH Osteoporosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jaglal SB, Weller I, Mamdani M, Hawker G, Kreder H, Jaakkimainen L, Adachi JD (2005) Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res 20(6): 898–905PubMedCrossRefGoogle Scholar
  2. Blahos J (2007) Treatment and prevention of osteoporosis. Wien Med Wochenschr 157(23–24): 589–592PubMedCrossRefGoogle Scholar
  3. Riggs BL, Parfitt MA (2005) Perspective Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodelling. J Bone Miner Res 20(2): 177–184PubMedCrossRefGoogle Scholar
  4. Sato M, Zeng GQ, Turner CH (1997) Biosynthetic human parathyroid hormone (1–34) effects on bone quality in aged ovariectomized rats. Endocrinology 138(10): 4330–4337PubMedCrossRefGoogle Scholar
  5. Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R (2001) Treatment with human parathyroid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28(2): 150–159PubMedCrossRefGoogle Scholar
  6. Sato M, Westmore M, Clendenon J, Smith S, Hannum B, Zeng GQ, Brommage R, Turner CH (2000) Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 11(10): 871–880PubMedCrossRefGoogle Scholar
  7. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357(9): 905–916PubMedCrossRefGoogle Scholar
  8. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19): 1434–1441PubMedCrossRefGoogle Scholar
  9. CPMP Guideline on the evaluation of new medicinal products in the treatment of primary osteoporosis. EMEA www.emea.europa.eu/pdfs/human/ewp/55295enfin.pdf
  10. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB (2007) Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146(5): 326–339PubMedGoogle Scholar
  11. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ (2005) PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353(6): 555–565PubMedCrossRefGoogle Scholar
  12. D'Amour P (2006) Circulating PTH molecular forms: What we know and what we don't. Kidney International 70: S29–S33CrossRefGoogle Scholar
  13. Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19(5): 745–751PubMedCrossRefGoogle Scholar
  14. Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV, for the EUROFORS Investigators (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93(3): 852–860PubMedCrossRefGoogle Scholar
  15. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) PaTH study investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausalosteoporosis. N Engl J Med 349(13): 1207–1215PubMedCrossRefGoogle Scholar
  16. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349(13): 1216–1226PubMedCrossRefGoogle Scholar
  17. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353(6): 566–575PubMedCrossRefGoogle Scholar
  18. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164(18): 2024–2030PubMedCrossRefGoogle Scholar
  19. Jódar-Gimeno E (2007) Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women. Clin Interv Aging 2(1): 163–174PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Medizinische Universität Wien/AKHUniversitätsklinik für Klinische Pharmakologie, AKH-WienViennaAustria

Personalised recommendations